Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S B Kaye

Showing results (391-400 of 411) with videos related to

Pageof 42
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
A phase I and pharmacokinetic study of LY231514, the multitargeted antifolateA C McDonald, P A Vasey, L Adams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase CD J Propper, A C McDonald, A Man, et al.
British Journal of Cancer|June 2, 2005
Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17)D P Dearnaley, S D Fossa, S B Kaye, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 30, 2014
A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†I A McNeish, J A Ledermann, L Webber, et al.
European Journal of Cancer (Oxford, England : 1990)|May 1, 1997
Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working PartyG M Duchesne, S P Stenning, N Aass, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2012
A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIGS Banerjee, G Rustin, J Paul, et al.
Nature Medicine|August 10, 2000
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancerF R Khuri, J Nemunaitis, I Ganly, et al.
Targeted Oncology|May 13, 2016
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor OlaparibJ Mateo, V Moreno, A Gupta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer TrialA Horwich, D T Sleijfer, S D Fosså, et al.
British Journal of Cancer|July 29, 1999
Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumoursS D Fosså, S P Stenning, A Gerl, et al.
Pageof 42

Showing results (391-400 of 411) with videos related to

Sort By:
Pageof 42
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
A phase I and pharmacokinetic study of LY231514, the multitargeted antifolateA C McDonald, P A Vasey, L Adams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase CD J Propper, A C McDonald, A Man, et al.
British Journal of Cancer|June 2, 2005
Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17)D P Dearnaley, S D Fossa, S B Kaye, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 30, 2014
A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†I A McNeish, J A Ledermann, L Webber, et al.
European Journal of Cancer (Oxford, England : 1990)|May 1, 1997
Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working PartyG M Duchesne, S P Stenning, N Aass, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2012
A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIGS Banerjee, G Rustin, J Paul, et al.
Nature Medicine|August 10, 2000
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancerF R Khuri, J Nemunaitis, I Ganly, et al.
Targeted Oncology|May 13, 2016
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor OlaparibJ Mateo, V Moreno, A Gupta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer TrialA Horwich, D T Sleijfer, S D Fosså, et al.
British Journal of Cancer|July 29, 1999
Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumoursS D Fosså, S P Stenning, A Gerl, et al.
Pageof 42